OliPass Corporation
https://www.olipass.com/front/eng/index.do
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OliPass Corporation
Latigo Raises $135m To Channel Vertex
The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.
Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.
Interview: OliPass An Oligonucleotide Outsider With Big Ambitions
South Korean bioventure OliPass tells Scrip how it intends to grab a leading position in the global antisense oligonucleotide drug sector using in-house developed technology that it says can both sharply lower prices and increase safety in the field, where it is initially focusing on novel pain therapies.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
-
Drug Discovery Tools
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice